A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Authors:

Abstract
Introduction Lenalidomide and dexamethasone (Rd) treatment is common for transplant ineligible (TI) patients (pts) with newly diagnosed multiple myeloma (NDMM).